In keeping with this hypothesis, correlations between skin rash and clinical benefit have been reported in connection with anti-epidermal growth factor receptor (EGFR) antibody, tyrosine kinase inhibitors, and capecitabine [20–22]. This evidence concerns the gene EGFR and Skin rash.